Common Contracts
2 similar Amalgamation Agreement contracts
Telferscot and Canntab Therapeutics Execute Definitive AgreementAmalgamation Agreement • February 18th, 2022
TORONTO, Ontario, January 15, 2018 – Telferscot Resources Inc. (CSE:TFS) (“Telferscot”) and Canntab Therapeutics Limited (“Canntab”) (and together the “Parties”) are pleased to announce execution of an Amalgamation Agreement (the “Agreement”) between the Parties pursuant to the Agreement. Canntab will amalgamate with a wholly-owned subsidiary of Telferscot and the Canntab shareholders will receive common shares of Telferscot in consideration for their shares of Canntab (the “Amalgamation”). Canntab has completed its $5-million financing, which was one of the conditions precedent to closing pursuant to the Agreement. The Parties have also satisfied the due diligence set forth in the Agreement and will be filing a listing statement with the Canadian Securities Exchange (“CSE”) for their review, comment and approval. This Listing Statement will provide detailed disclosure of the new business and related risk factors. The transaction proposed will constitute a Fundamental Change pursuant t
Telferscot and Canntab Therapeutics Execute Definitive AgreementAmalgamation Agreement • January 15th, 2018
TORONTO, Ontario, January 15, 2018 – Telferscot Resources Inc. (CSE:TFS) (“Telferscot”) and Canntab Therapeutics Limited (“Canntab”) (and together the “Parties”) are pleased to announce execution of an Amalgamation Agreement (the “Agreement”) between the Parties pursuant to the Agreement. Canntab will amalgamate with a wholly-owned subsidiary of Telferscot and the Canntab shareholders will receive common shares of Telferscot in consideration for their shares of Canntab (the “Amalgamation”). Canntab has completed its $5-million financing, which was one of the conditions precedent to closing pursuant to the Agreement. The Parties have also satisfied the due diligence set forth in the Agreement and will be filing a listing statement with the Canadian Securities Exchange (“CSE”) for their review, comment and approval. This Listing Statement will provide detailed disclosure of the new business and related risk factors. The transaction proposed will constitute a Fundamental Change pursuant t
